Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
Objective The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy.Methods Screening for the study was carried out using MEDLINE, Cochr...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-02-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/5/1/e000763.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720623050260480 |
|---|---|
| author | Adeline Ruyssen-Witrand Bénédicte Champs Yannick Degboé Thomas Barnetche Alain Cantagrel Arnaud Constantin |
| author_facet | Adeline Ruyssen-Witrand Bénédicte Champs Yannick Degboé Thomas Barnetche Alain Cantagrel Arnaud Constantin |
| author_sort | Adeline Ruyssen-Witrand |
| collection | DOAJ |
| description | Objective The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy.Methods Screening for the study was carried out using MEDLINE, Cochrane and Embase, from the inception of the database to December 2017. Randomised controlled trials (RCTs) of anti-tumour necrosis factor (TNF), anti-interleukin (IL)12/23, anti-IL23 and anti-IL17 agents for the treatment of PsA or psoriasis were included. Two investigators independently extracted MACEs or CHF data reported during the placebo-controlled phase. The primary outcome measures were the incidence of MACEs or CHF.Results Of 753 references screened, 62 articles were selected, and 12 articles were added by manual searches. Accordingly 77 RCTs were included in the meta-analysis (MA) (10 174 patient-years (P-Y)). No significant difference was observed in MACE incidences in patients receiving anti-TNF, anti-IL12/23, anti-IL23 or anti-IL17 agents in comparison to the placebo. However, 10 MACEs were observed in the anti-IL12/23 group (1150 P-Y) compared with 1 in the placebo group (652 P-Y), with 0.01 −0.00 to 0.02 event/P-Y risk difference, which is not statistically significant. This trend was not observed in the anti-IL23 group. No significant difference was observed in CHF incidence in patients receiving biological agents in comparison to placebo.Conclusion This MA of 77 RCTs did not reveal any significant change in the short-term risk of MACE or CHF in patients with PsA or psoriasis initiating a biological therapy. |
| format | Article |
| id | doaj-art-d6d90a77538245d886f3eb7c7709d570 |
| institution | DOAJ |
| issn | 2056-5933 |
| language | English |
| publishDate | 2019-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-d6d90a77538245d886f3eb7c7709d5702025-08-20T03:11:52ZengBMJ Publishing GroupRMD Open2056-59332019-02-015110.1136/rmdopen-2018-000763Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trialsAdeline Ruyssen-Witrand0Bénédicte Champs1Yannick Degboé2Thomas Barnetche3Alain Cantagrel4Arnaud Constantin51 Rhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France1 Rhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France2 Rhumatologie, Hôpital Pellegrin, Bordeaux Université, Bordeaux, FranceRheumatology Department, FHU ACRONIM, University Hospital Centre Bordeaux, Bordeaux, Nouvelle-Aquitaine, France1 Rhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, France1 Rhumatologie, Hôpital Purpan, Toulouse III Université, Toulouse, FranceObjective The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy.Methods Screening for the study was carried out using MEDLINE, Cochrane and Embase, from the inception of the database to December 2017. Randomised controlled trials (RCTs) of anti-tumour necrosis factor (TNF), anti-interleukin (IL)12/23, anti-IL23 and anti-IL17 agents for the treatment of PsA or psoriasis were included. Two investigators independently extracted MACEs or CHF data reported during the placebo-controlled phase. The primary outcome measures were the incidence of MACEs or CHF.Results Of 753 references screened, 62 articles were selected, and 12 articles were added by manual searches. Accordingly 77 RCTs were included in the meta-analysis (MA) (10 174 patient-years (P-Y)). No significant difference was observed in MACE incidences in patients receiving anti-TNF, anti-IL12/23, anti-IL23 or anti-IL17 agents in comparison to the placebo. However, 10 MACEs were observed in the anti-IL12/23 group (1150 P-Y) compared with 1 in the placebo group (652 P-Y), with 0.01 −0.00 to 0.02 event/P-Y risk difference, which is not statistically significant. This trend was not observed in the anti-IL23 group. No significant difference was observed in CHF incidence in patients receiving biological agents in comparison to placebo.Conclusion This MA of 77 RCTs did not reveal any significant change in the short-term risk of MACE or CHF in patients with PsA or psoriasis initiating a biological therapy.https://rmdopen.bmj.com/content/5/1/e000763.full |
| spellingShingle | Adeline Ruyssen-Witrand Bénédicte Champs Yannick Degboé Thomas Barnetche Alain Cantagrel Arnaud Constantin Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials RMD Open |
| title | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials |
| title_full | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials |
| title_fullStr | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials |
| title_full_unstemmed | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials |
| title_short | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials |
| title_sort | short term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy a meta analysis of randomised controlled trials |
| url | https://rmdopen.bmj.com/content/5/1/e000763.full |
| work_keys_str_mv | AT adelineruyssenwitrand shorttermriskofmajoradversecardiovasculareventsorcongestiveheartfailureinpatientswithpsoriaticarthritisorpsoriasisinitiatingabiologicaltherapyametaanalysisofrandomisedcontrolledtrials AT benedictechamps shorttermriskofmajoradversecardiovasculareventsorcongestiveheartfailureinpatientswithpsoriaticarthritisorpsoriasisinitiatingabiologicaltherapyametaanalysisofrandomisedcontrolledtrials AT yannickdegboe shorttermriskofmajoradversecardiovasculareventsorcongestiveheartfailureinpatientswithpsoriaticarthritisorpsoriasisinitiatingabiologicaltherapyametaanalysisofrandomisedcontrolledtrials AT thomasbarnetche shorttermriskofmajoradversecardiovasculareventsorcongestiveheartfailureinpatientswithpsoriaticarthritisorpsoriasisinitiatingabiologicaltherapyametaanalysisofrandomisedcontrolledtrials AT alaincantagrel shorttermriskofmajoradversecardiovasculareventsorcongestiveheartfailureinpatientswithpsoriaticarthritisorpsoriasisinitiatingabiologicaltherapyametaanalysisofrandomisedcontrolledtrials AT arnaudconstantin shorttermriskofmajoradversecardiovasculareventsorcongestiveheartfailureinpatientswithpsoriaticarthritisorpsoriasisinitiatingabiologicaltherapyametaanalysisofrandomisedcontrolledtrials |